Creso Pharma has announced that CLV Frontier Brands, its equal one-third joint venture with UK-based Baltic Beer Company Ltd and Canadian TSX Venture incorporated LGC Capital, is planning to have its first beers and tonics on sale in Europe and Canada during the summer, with global sales to follow thereafter.
CLV is developing a bespoke and unique range of beers and tonics at its newly-built facilities in Europe, with test brewing well advanced.
Creso is also pleased to announce that the TSX Venture Exchange has conditionally accepted LGC’s joint venture investment in CLV, subject to LGC filing standard documentation with the Exchange.
“We see CLV as an exciting business partnership that we believe can add significant sales revenues to Creso Pharma over the coming years. Full details of the beer and tonic ranges will be released when CLV debuts its products and branding at a world-wide product launch. Europe will be the initial focus for sales, as Europe is the home market for the Baltic Beer Company’s multi award winning Viru beer. The company also plans to launch in Canada this summer,” said Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma.
CLV’s beers contain terpenes, which carry the flavour and aroma of cannabis, but which do not contain THC or CBD or any other cannabinoids. The terpenes are extracted from various plant sources, all of which are food-grade, 100% natural and non-genetically modified (GMO) ingredients. The terpenes are pure, not contaminated with any other ingredient, and safe for human consumption as flavouring and food additive ingredients, meeting the criteria of FDA/FEMA GRAS (Generally Recognized as Safe) for human consumption. The terpenes are introduced to the beer at the post-fermentation stage in much the same manner as hop extracts are added.
CLV will have vast commercialisation reach spanning various continents leveraging the networks of all three companies.